Long-Term Outcomes in Idiopathic Pulmonary Arterial Hypertension (iPAH) Treated in the Netherlands, 1998-2007.

2009 ◽  
Author(s):  
W Jacobs ◽  
M Brand ◽  
D Rosenberg ◽  
B Schaaf ◽  
A Boonstra ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
The Netherlands ◽  
Arterial Hypertension ◽  
Idiopathic Pulmonary Arterial Hypertension ◽  
Long Term Outcomes ◽  
Pulmonary Arterial

scholarly journals Occult catheter rupture causing episodic symptoms in a patient treated with epoprostenol

2017 ◽  
Vol 8 (1) ◽  
pp. 204589321774805 ◽  
Author(s):  
Barbara L. LeVarge ◽  
Anica C. Law ◽  
Blanche Murphy
Keyword(s):  
Pulmonary Hypertension ◽  
Pulmonary Arterial Hypertension ◽  
Adverse Events ◽  
Arterial Hypertension ◽  
Long Term Outcomes ◽  
Pulmonary Arterial

Infection, thrombosis, and catheter dislodgment are well-recognized potential complications of chronic intravenous prostanoid therapy for pulmonary arterial hypertension. As long-term outcomes of pulmonary hypertension patients improve, novel adverse events are likely to arise. We describe the sudden development of unexplained hypotension and lightheadedness in a patient receiving intravenous epoprostenol for several years, ultimately determined to be due to an unusual catheter complication, not previously described in this population.

scholarly journals Long-Term Survival in Idiopathic Pulmonary Arterial Hypertension Associated with Massive Pulmonary Artery Dilation

2011 ◽  
Vol 18 (3) ◽  
pp. e50-e51 ◽  
Author(s):  
Vanja Petrovic ◽  
Christopher J Ryerson ◽  
Robert D Levy
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Present Report ◽  
Pulmonary Arteries ◽  
Idiopathic Pulmonary Arterial Hypertension ◽  
Channel Blockers ◽  
Term Survival ◽  
Long Term Survival ◽  
Pulmonary Arterial

The present report describes two patients with long-term survival after being diagnosed with idiopathic pulmonary arterial hypertension more than 20 years earlier. Both patients were treated with calcium channel blockers for several years and are currently maintained on bosentan, an oral endothelin receptor antagonist. Severe dilation of the main pulmonary arteries is present in both patients and may be related to long-term survival with idiopathic pulmonary arterial hypertension.

Sign in / Sign up

Export Citation Format

Share Document